Beta-adrenoceptor tocolysis and effects on the heart of fetus and neonate. A review.
A literature of 92 scientific papers addressing the effects of beta-adrenoceptor stimulation on the heart have been collected with the support of a computer-based MEDLINE system and critically examined. Neither in animal experiments nor in a wide clinical use of tocolytics for more than two decades has a risk for the hearts of fetus and neonate been confirmed, because there is no or only very little stimulating action on the beta-adrenoceptors of fetal and newborn's hearts as their sympathetic innervation is still immature.
Kast
A
A
Corporate Division of Non-Clinical Drug Safety, Boehringer Ingelheim KG, Fed. Rep. of Germany.
Hermer
M
M
D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D005260:Female; D005280:Fenoterol / Q000009:adverse effects; D005318:Fetal Heart / Q000187:drug effects*; D006321:Heart / Q000187:drug effects; D006340:Heart Rate, Fetal / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D012312:Ritodrine / Q000009:adverse effects; D013726:Terbutaline / Q000009:adverse effects; D015145:Tocolysis / Q000009:adverse effects*; D015149:Tocolytic Agents / Q000009:adverse effects*
D000318:Adrenergic beta-Agonists; D015149:Tocolytic Agents; D005280:Fenoterol; D012312:Ritodrine; D013726:Terbutaline